Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer-the Experience of a Tertiary Cancer Center.

oxaliplatin backbone) in first- or second-line treatment, a trend toward a greater OS, TTF, PFS1, and PFS2 was observed for irinotecan-based regimens compared to oxaliplatin-based chemotherapy in both groups, however these differences did not reach statistical significance ( Table 6 ).

also in 111,027 other papers